Free tool
FAERS Monitor: Beyfortus
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761328 or its brand name (Beyfortus, Nirsevimab-Alip). Reports on generic versions are filed under their own applications.
Reports
1,793
Serious
1,142
64% of reports
Hospitalization
762
Death reported
41
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective324
- respiratory syncytial virus bronchiolitis302
- respiratory syncytial virus infection251
- incorrect dose administered234
- bronchiolitis157
- pyrexia114
- cough112
- extra dose administered84
- expired product administered50
- respiratory syncytial virus test positive50
- dyspnoea46
- wheezing44
- apnoea42
- rash39
- product storage error38
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2023 | 143 |
| 2024 | 450 |
| 2025 | 772 |
| 2026 | 428 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,366 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| respiratory syncytial virus bronchiolitisSignal | 302 | 7387.3 | 6445.9 | 1,364,541 |
| respiratory syncytial virus test positiveSignal | 50 | 899.0 | 676.9 | 40,833 |
| bronchiolitisSignal | 157 | 547.7 | 469.9 | 81,342 |
| respiratory syncytial virus infectionSignal | 251 | 348.2 | 309.8 | 84,080 |
| apnoeaSignal | 42 | 63.6 | 47.1 | 2,514 |
| extra dose administeredSignal | 84 | 24.4 | 19.8 | 1,859 |
| expired product administeredSignal | 50 | 17.7 | 13.4 | 770 |
| incorrect dose administeredSignal | 234 | 12.0 | 10.7 | 2,380 |
| wheezingSignal | 44 | 8.7 | 6.5 | 293 |
| product storage errorSignal | 38 | 5.1 | 3.7 | 121 |
| coughSignal | 112 | 4.7 | 3.9 | 325 |
| pyrexiaSignal | 114 | 3.9 | 3.2 | 243 |
| drug ineffectiveSignal | 324 | 2.9 | 2.6 | 423 |
| rash | 39 | 1.0 | 0.8 | 0 |
| dyspnoea | 46 | 1.0 | 0.7 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.